Home  /  Resource Library  /  Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

Results of a phase II study investigating parsaclisib for treatment of relapsed DLBCL.